Update on peritoneal dialysis solutions

Kidney International

Volumn 71, Issue 6, 2007, Pages 486-490

  McIntyre, C W ^a,b,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

AGEs; Chronic kidney disease; Glucose; Glucose degradation products; Peritoneal dialysis

Indexed keywords

EXTRANEAL; NUTRINEAL; PERITONEAL DIALYSIS FLUID; SODIUM CHLORIDE; WATER;

BODY COMPOSITION; CARDIOVASCULAR RISK; HUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

BICARBONATES; BODY COMPOSITION; BODY WATER; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; HUMANS; KIDNEY DISEASES; LACTATES; PERITONEAL DIALYSIS; PERITONEUM;

EID: 33947125636     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002109     Document Type: Short Survey

References (47)

1. Feriani M. Buffers: bicarbonate, lactate and pyruvate. Kidney Int 1996; 56(Suppl): S75-S80.
2. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of microangiopathy. Perit Dial Bull 1985; 9: 41-45.
3. Mactier RA, Sprosen TS, Gokal R et al. Bicarbonate and bicarbonate/ lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53: 1061-1067.
4. Hoff CM. In vitro biocompatibility performance of physioneal. Kidney Int Suppl 2003; 88: S57-S74.
5. Witowski J, Jorres A, Korybalska K et al. Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int Suppl 2003; 84: S148-S151.
6. Pischetsreider M. Chemistry of glucose and biochemical pathways of biological interest. Perit Dial Int 2000; 20(Suppl 2): S26-S30.
7. Krediet RT, Zweers MM, van der Wal AC et al. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20(Suppl 2): S19-S25.
8. Passlick-Deetjen J, Lage C. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. Perit Dial Int 2000; 20(Suppl 2): S42-S47.
9. Cooker LA, Choo CG, Luneburg P et al. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 1999; 15: 17-20.
10. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-986.
11. Frampton JE, Plosker GL. Icodextrin: a review of its use in peritoneal dialysis. Drugs 2003; 63: 2079-2105.
12. Taylor GS, Patel V, Spencer S et al. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 2002; 58: 445-450.
13. Chen CJ, Moberly JB, Martis L. New developments in peritoneal dialysis solutions. Adv Perit Dial 1998; 14: 116-119.
14. Catalan MP, Santamaria B, Reyero A et al. 3,4-di-deoxyglucosone-3- ene promotes leukocyte apoptosis. Kidney Int 2005; 68: 1303-1311.
15. Welten AG, Schalkwijk CG, ter Wee PM et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23: 213-221.
16. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186.
17. Witowski J, Korybalska K, Ksiazek K et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19: 917-924.
18. Morgan LW, Wieslander A, Davies M et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003; 64: 1854-1866.
19. Davies SJ, Brown EA, Frandsen NE et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615.
20. Martikainen TA, Teppo AM, Gronhagen-Riska C et al. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25: 453-460.
21. Fusshoeller A, Plail M, Grabensee B et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106.
22. Van Bree M, Miseraque D, Story KO et al. J Am Soc Nephrol 2002; 13: S43A.
23. Dratwa M, Wilkie M, Ryckelynck JP et al. Clinical experience with two physiologic bicarbonate/lactate peritoneal dialysis solutions in automated peritoneal dialysis. Kidney Int Suppl 2003; 88: S105-S113.
24. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890.
25. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344.
26. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191.
27. Asghar RB, Diskin AM, Spanel P et al. Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane. J Am Soc Nephrol 2005; 16: 437-443.
28. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523.
29. le Poole CY, van Ittersum FJ, Weijmer MC et al. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20: 170-176.
30. Justo P, Sanz AB, Egido J et al. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54: 2424-2429.
31. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480-1486.
32. Delarue J, Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 2001; 37: S103-S107.
33. Selby NM, Fialova J, McIntyre CW. The systemic haemodynamic and metabolic effects of peritoneal dialysis fluids. Nephrol Dial Transplant 2006 (E-pub ahead of print).
34. Bredie SJ, Bosch FH, Demacker PN et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21: 275-281.
35. McIntyre CW, Selby NM, Sigrist M et al. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant 2006; 8: 2210-2216.
36. McIntyre CW, Sigrist M, Selby NM. Functionally significant progressive skeletal muscle wasting in CKD 4 and CKD 5 (PD and HD) patients. (ASN PO832) 2005; 16: 301A.
37. Delarue J, Maingourd C, Objois M et al. Effects of an amino acid dialysate on leucine metabolism in continuous ambulatory peritoneal dialysis patients. Kidney Int 1999; 56: 1934-1943.
38. Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157.
39. Perez-Fontan M, Cordido F, Rodriguez-Carmona A et al. Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int 2005; 68: 2877-2885.
40. Kim DJ, Oh DJ, Kim B et al. The effect of continuous ambulatory peritoneal dialysis on change in serum leptin. Perit Dial Int 1999; 19(Suppl 2): S172-S175.
41. Teta D, Tedjani A, Burnier M et al. Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes. Nephrol Dial Transplant 2005; 20: 1329-1335.
42. Furuya R, Odamaki M, Kumagai H et al. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21: 494-498.
43. Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 707-714.
44. Sigrist M, Bungay P, McIntyre CW. Functionally significant vascular calcification is rapidly progressive in CKD 4 and 5 patients. (ASN PO311) 2005; 16: 187A.
45. Sigrist M, Bungay P, McIntyre CW. Determinants of progressive vascular calcification in CKD 4 and 5 patients. 2006 (Abstract submitted ASN) 17: 507A.
46. Tjiong HL, van den Berg JW, Wattimena JL et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
47. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005; 25: 248-255.